<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37194710</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1525-6049</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Renal failure</Title><ISOAbbreviation>Ren Fail</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>2207671</StartPage><MedlinePgn>2207671</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2207671</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/0886022X.2023.2207671</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Belimumab is the first biological agent approved for the treatment of systemic lupus erythematosus (SLE), but the efficacy of belimumab for lupus nephritis (LN) is not clear. We conducted this meta-analysis and systematic review to compare the efficacy and safety of belimumab with those of conventional therapy for LN.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">PubMed, EMBASE, Cochrane Library, Clinical Trials.gov were searched in 31 December 2022 to identify relevant adult human studies reporting effectiveness outcomes of belimumab in patients with LN. Review manager (RevMan 5.4) was used for data analysis with fixed effects model based on heterogeneities.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Six randomized controlled trials (RCTs) were included in the quantitative analysis. A total of 2960 participants were identified. Belimumab plus standard therapy significantly improved total renal response rates (RR, 1.31; 95% CI, 1.11-1.53; <i>p</i>&#x2009;=&#x2009;0.001) and complete renal RRs (1.47; 95% CI, 1.07-2.02; <i>p</i>&#x2009;=&#x2009;0.02) compared with the control plus standard therapy group. It significantly reduced the risk of renal flare (RR, 0.51; 95% CI, 0.37-0.69; <i>p</i>&#x2009;&lt;&#x2009;0.001) and renal function worsening or progression to end-stage renal disease (ESRD) (RR, 0.56; 95% CI, 0.40-0.79; <i>p</i>&#x2009;=&#x2009;0.001). When assessed with the incidence of adverse events, no significant differences between the two groups were observed for the occurrence of treatment-related adverse events (RR, 1.04; 95% CI, 0.99-1.09; <i>p</i>&#x2009;=&#x2009;0.12).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">This meta-analysis showed that belimumab plus standard therapy was more effective and had a favorable safety in patients with LN.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Han</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital of Shandong First Medical University &amp; Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Institute of Nephrology, Jinan, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital of Shandong First Medical University &amp; Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Institute of Nephrology, Jinan, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital of Shandong First Medical University &amp; Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Institute of Nephrology, Jinan, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Na</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital of Shandong First Medical University &amp; Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Institute of Nephrology, Jinan, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Dongmei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital of Shandong First Medical University &amp; Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Institute of Nephrology, Jinan, PR China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ren Fail</MedlineTA><NlmUniqueID>8701128</NlmUniqueID><ISSNLinking>0886-022X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>73B0K5S26A</RegistryNumber><NameOfSubstance UI="C511911">belimumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Belimumab</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37194710</ArticleId><ArticleId IdType="pmc">PMC10193908</ArticleId><ArticleId IdType="doi">10.1080/0886022X.2023.2207671</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fanouriakis A, Tziolos N, Bertsias G, et al. . Update Omicron the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">33051219</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward MM. Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996&#x2013;2004. J Rheumatol. 2009;36(1):63&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2679678</ArticleId><ArticleId IdType="pubmed">19004042</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassia M, Alberici F, Gallieni M, et al. . Lupus nephritis and B-cell targeting therapy. Expert Rev Clin Immunol. 2017;13(10):951&#x2013;962.</Citation><ArticleIdList><ArticleId IdType="pubmed">28800401</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahajan A, Amelio J, Gairy K, et al. . Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. Lupus. 2020;29(9):1011&#x2013;1020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7425376</ArticleId><ArticleId IdType="pubmed">32571142</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodis I, Stockfelt M, Sjowall C.. B cell therapy in systemic lupus erythematosus: from rationale to clinical practice. Front Med (Lausanne). 2020;7:316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7381321</ArticleId><ArticleId IdType="pubmed">32754605</ArticleId></ArticleIdList></Reference><Reference><Citation>Stohl W, Hilbert DM.. The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol. 2012;30(1):69&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264947</ArticleId><ArticleId IdType="pubmed">22231104</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Bertsias G.. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology (Oxford). 2020;59(5):v69&#x2013;v81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7719039</ArticleId><ArticleId IdType="pubmed">33280011</ArticleId></ArticleIdList></Reference><Reference><Citation>Pl&#xfc;&#xdf; M, Tampe B, Niebusch N, et al. . Clinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus. Front Med (Lausanne). 2020;7:222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267006</ArticleId><ArticleId IdType="pubmed">32537456</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Radin M, Yazdany J, et al. . Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: a systematic review. Autoimmun Rev. 2017;16(3):287&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">28147262</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodis I, Vital EM, Hassan SU, et al. . De novo lupus nephritis during treatment with belimumab. Rheumatology (Oxford). 2021;60(9):4348&#x2013;4354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409994</ArticleId><ArticleId IdType="pubmed">33341888</ArticleId></ArticleIdList></Reference><Reference><Citation>Br&#xe5;dland S, Andel P, Diamandopoulos A, et al. . Pos1451 developing a tool to measure the learning curve: enthesitis ultrasound in psoriasis arthritis. Ann Rheum Dis. 2021;80(1):1009.2&#x2013;1010.</Citation></Reference><Reference><Citation>Furie R, Petri M, Zamani O, et al. . A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918&#x2013;3930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5007058</ArticleId><ArticleId IdType="pubmed">22127708</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarra SV, Guzman RM, Gallacher AE, et al. . Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296403</ArticleId></ArticleIdList></Reference><Reference><Citation>Dooley MA, Houssiau F, Aranow C, et al. . Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus. 2013;22(1):63&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">23263865</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Rovin BH, Houssiau F, et al. . Two-Year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117&#x2013;1128.</Citation><ArticleIdList><ArticleId IdType="pubmed">32937045</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjowall C, Coster L.. Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity. Scand J Rheumatol. 2014;43(5):428&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">24689946</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui-Yuen JS, Reddy A, Taylor J, et al. . Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. J Rheumatol. 2015;42(12):2288&#x2013;2295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5031077</ArticleId><ArticleId IdType="pubmed">26523030</ArticleId></ArticleIdList></Reference><Reference><Citation>Staveri C, Karokis D, Liossis SC.. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab. Semin Arthritis Rheum. 2017;46(6):788&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">27793432</ArticleId></ArticleIdList></Reference><Reference><Citation>Anjo C, Mascaro JM, Jr., Espinosa G, et al. . Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting. Scand J Rheumatol. 2019;48(6):469&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">31264525</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Green S, editors.. Guide to the contents of a cochrane protocol and review. 2008. p. 51&#x2013;79. (Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series).</Citation></Reference><Reference><Citation>Stohl W, Schwarting A, Okada M, et al. . Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two&#x2013;week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2017;69(5):1016&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5434872</ArticleId><ArticleId IdType="pubmed">28118533</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, Bass D, Chu M, et al. . Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: a subgroup analysis from a phase 3 randomized placebo-controlled trial. Mod Rheumatol. 2020;30(2):313&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">31199180</ArticleId></ArticleIdList></Reference><Reference><Citation>Atisha-Fregoso Y, Malkiel S, Harris KM, et al. . Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol. 2021;73(1):121&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7839443</ArticleId><ArticleId IdType="pubmed">32755035</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginzler E, Guedes Barbosa LS, D&#x2019;Cruz D, et al. . Phase III/IV, randomized, Fifty-Two-Week study of the efficacy and safety of belimumab in patients of black African ancestry with systemic lupus erythematosus. Arthritis Rheumatol. 2022;74(1):112&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9300099</ArticleId><ArticleId IdType="pubmed">34164944</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S, Fedoriw Y, Brenneman EK, et al. . BAFF induces tertiary lymphoid structures and positions T cells within the glomeruli during lupus nephritis. J Immunol. 2017;198(7):2602&#x2013;2611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360485</ArticleId><ArticleId IdType="pubmed">28235864</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent FB, Morand EF, Schneider P, et al. . The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10(6):365&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">24614588</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Davidson A.. BAFF and selection of autoreactive B cells. Trends Immunol. 2011;32(8):388&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3151317</ArticleId><ArticleId IdType="pubmed">21752714</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Neuwelt CM, Wallace DJ, et al. . Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4548300</ArticleId><ArticleId IdType="pubmed">20039413</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Furie R, Latinis K, et al. . Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64(4):1215&#x2013;1226.</Citation><ArticleIdList><ArticleId IdType="pubmed">22231479</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenstein MR, Wing C.. The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol. 2016;12(6):367&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">26888554</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraaij T, Arends EJ, van Dam LS, et al. . Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results. Nephrol Dial Transplant. 2021;36(8):1474&#x2013;1483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8311580</ArticleId><ArticleId IdType="pubmed">32591783</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraaij T, Huizinga TWJ, Rabelink TJ, et al. . Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology. 2014;53(11):2122&#x2013;2124.</Citation><ArticleIdList><ArticleId IdType="pubmed">25205827</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonetta F, Allali D, Roux-Lombard P, et al. . Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab. Joint Bone Spine. 2017;84(2):235&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">27238199</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassan SU, Md Yusof MY, Emery P, et al. . Biologic sequencing in systemic lupus erythematosus: after secondary non-response to rituximab, switching to humanised anti-CD20 agent is more effective than belimumab. Front Med (Lausanne). 2020;7:498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7481350</ArticleId><ArticleId IdType="pubmed">32984378</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward M, Tektonidou MG.. Belimumab as add-on therapy in lupus nephritis. N Engl J Med. 2020;383(12):1184&#x2013;1185.</Citation><ArticleIdList><ArticleId IdType="pubmed">32937052</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Dasgupta A, Ward MM.. Risk of end-stage renal disease in patients with lupus nephritis, 1971&#x2013;2015: a systematic review and bayesian meta-analysis. Arthritis Rheumatol. 2016;68(6):1432&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5071782</ArticleId><ArticleId IdType="pubmed">26815601</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Huang S, Chen T, et al. . Machine learning for prediction and risk stratification of lupus nephritis renal flare. Am J Nephrol. 2021;52(2):152&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">33744876</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh SV, Nagaraja HN, Hebert L, et al. . Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis. Clin J Am Soc Nephrol. 2014;9(2):279&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3913239</ArticleId><ArticleId IdType="pubmed">24262502</ArticleId></ArticleIdList></Reference><Reference><Citation>Binda V, Trezzi B, Del Papa N, et al. . Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient). J Nephrol. 2020;33(5):1019&#x2013;1025.</Citation><ArticleIdList><ArticleId IdType="pubmed">32002799</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, Zhou Q, Wang D, et al. . Efficacy and safety of belimumab in systemic lupus erythematosus patients with severe lupus nephritis requiring renal replacement therapy. Lupus. 2022;31(12):1456&#x2013;1467.</Citation><ArticleIdList><ArticleId IdType="pubmed">35960182</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Zeng M, Ge Y, et al. . Effectiveness and safety of belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: a case report and literature review. Front Immunol. 2022;13:977377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9511409</ArticleId><ArticleId IdType="pubmed">36172377</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh JA, Shah NP, Mudano AS.. Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev. 2021;2(2):CD010668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095005</ArticleId><ArticleId IdType="pubmed">33631841</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Sawah S, Zhang X, Zhu B, et al. . Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins lupus cohort. Lupus Sci Med. 2015;2(1):e000066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4378372</ArticleId><ArticleId IdType="pubmed">25861455</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, Navarra S, Petri MA, et al. . Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2013;22(2):144&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">23213069</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise LM, Stohl W.. The safety of belimumab for the treatment of systemic lupus erythematosus. Expert Opin Drug Saf. 2019; 18(12):1133&#x2013;1144.</Citation><ArticleIdList><ArticleId IdType="pubmed">31657965</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>